Sutro Biopharma says Phase 1 STRO-004 trial initial results due mid-2026

• Sutro Biopharma disclosed new preclinical data at AACR 2026 showing STRO-004 delivered consistent tumor control across multiple tissue factor-expressing solid tumor models, supporting expectations for stronger clinical response durability versus current benchmarks.
• A Phase 1 study of STRO-004 in refractory or recurrent metastatic solid tumors remains ongoing, with initial clinical results expected in mid-2026.
• Additional AACR posters presented preclinical findings for STRO-006 and STRO-227, with both programs showing dose-responsive antitumor activity across several solid tumor models.
• Sutro guided to an IND submission for STRO-006 in 2026, positioning it as a near-term pipeline catalyst.
• Company expects to file an IND for dual-payload ADC STRO-227 in late 2026, marking its first wholly owned dual-payload candidate slated for clinical entry.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sutro Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604191945PRIMZONEFULLFEED9692714) on April 19, 2026, and is solely responsible for the information contained therein.